Dimensional Fund Advisors LP Sells 41,658 Shares of Labcorp Holdings Inc. $LH

Key Points

• Dimensional Fund Advisors trimmed its Labcorp position by 3.2%, selling 41,658 shares in Q3 and now holds 1,246,556 shares (~1.50% of the company) valued at about $357.8 million.
• Q results and guidance: Labcorp beat EPS estimates ($4.07 vs. $3.95) while revenue ($3.52B) slightly missed expectations, with revenue up 5.6% YoY and FY 2026 EPS guidance set at $17.55–$18.25.
• Insider selling: CEO Adam Schechter sold 8,705 shares (~$2.44M) and insiders have sold 16,113 shares (~$4.55M) in the last 90 days, while insiders own just 0.84% of the stock.

Dimensional Fund Advisors LP lowered its position in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 3.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,246,556 shares of the medical research company's stock after selling 41,658 shares during the period. Dimensional Fund Advisors LP owned about 1.50% of Labcorp worth $357,794,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Caldwell Trust Co bought a new position in shares of Labcorp during the 2nd quarter worth approximately $25,000. Financial Gravity Companies Inc. purchased a new stake in shares of Labcorp during the second quarter valued at approximately $26,000. Motco bought a new stake in Labcorp during the third quarter worth $32,000. Hantz Financial Services Inc. boosted its position in Labcorp by 48.8% in the third quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company's stock worth $35,000 after purchasing an additional 40 shares during the last quarter. Finally, Headlands Technologies LLC grew its stake in Labcorp by 300.0% in the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company's stock valued at $34,000 after purchasing an additional 96 shares during the period. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Labcorp Price Performance

LH opened at $275.80 on Friday. The firm has a 50-day moving average price of $270.68 and a 200-day moving average price of $270.30. Labcorp Holdings Inc. has a twelve month low of $209.38 and a twelve month high of $293.72. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $22.73 billion, a price-to-earnings ratio of 26.37, a PEG ratio of 1.92 and a beta of 1.01.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, beating analysts' consensus estimates of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The company had revenue of $3.52 billion for the quarter, compared to analysts' expectations of $3.56 billion. During the same period in the prior year, the company posted $3.45 EPS. Labcorp's revenue was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Equities analysts expect that Labcorp Holdings Inc. will post 16.01 EPS for the current year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be given a $0.72 dividend. The ex-dividend date is Friday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp's payout ratio is 27.53%.

Analyst Ratings Changes

LH has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Labcorp from a "hold" rating to a "buy" rating in a research note on Friday, January 23rd. Robert W. Baird raised their price objective on shares of Labcorp from $313.00 to $326.00 and gave the stock an "outperform" rating in a report on Wednesday, February 18th. Weiss Ratings upgraded shares of Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, February 10th. Piper Sandler increased their target price on shares of Labcorp from $270.00 to $300.00 and gave the company a "neutral" rating in a research report on Tuesday, February 24th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Labcorp in a report on Tuesday, February 17th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $304.82.

Insider Buying and Selling

In related news, CEO Adam H. Schechter sold 8,705 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the sale, the chief executive officer owned 80,773 shares of the company's stock, valued at approximately $22,613,209.08. This represents a 9.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Brian J. Caveney sold 1,500 shares of the firm's stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total value of $429,465.00. Following the completion of the transaction, the executive vice president owned 30,107 shares of the company's stock, valued at approximately $8,619,935.17. This represents a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,113 shares of company stock valued at $4,547,450 in the last ninety days. 0.84% of the stock is owned by company insiders.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.